The potential for receptor competition, the unknown risk profile, and the complete lack of scientific data make it a path fraught with uncertainty

A same-day or prompt call is appropriate for: Pain that is moderate, severe, or increasing rather than improving A headache that is severe, unusual for you, persistent, or not responding to the plan you were given Spreading redness, warmth, swelling, pus, fever, or chills Marked one-sided swelling or a rapidly expanding bruise New drooping, asymmetry, smile change, chewing difficulty, or neck weakness Persistent numbness, burning, electric-shock pain, or unusual sensory changes Eye irritation, inability to close the eye, light sensitivity, or visual symptoms Pain that continues beyond the recovery window described by your clinician Concern about the product source, dose, injector, or treatment setting Information to Give the Clinician Date and time of treatment Product name, if known Areas treated and why When the pain started Pain severity from 0 to 10 Whether it is improving or worsening Associated redness, fever, weakness, drooping, vision change, or swallowing/breathing symptoms Medicines taken since treatment Clear photographs when visible changes are present When Pain Requires Urgent or Emergency Care The current FDA prescribing information carries a boxed warning about distant spread of botulinum toxin effects

Semaglutide Developed and manufactured by Novo Nordisk, semaglutide is a weekly injection that was approved by the FDA to treat type 2 diabetes under the name Ozempic in December 2017
Weight management after thyroidectomy is clinically complex